Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months
Company Confirms Trials On Track For Approval Before Lucentis EU Patent Expiry
Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.
You may also be interested in...
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Privately-owned Stada provided little insight into the exact mechanics of its operations for the first six months of 2020 but nevertheless said it had enjoyed an “above-market sales and earnings increase.” However, a raft of one-off expenses bit into the German firm’s profitability.
Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.